Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The industry rank for Siemens Healthineers AG's 9-Day RSI or its related term are showing as below:
LTS:0PMJ's 9-Day RSI is ranked worse than 73.59% of 867
companies
in the Medical Devices & Instruments industry
Industry Median: 45.51
vs LTS:0PMJ: 56.36
Siemens Healthineers AG (LTS:0PMJ) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Siemens Healthineers AG 9-Day RSI Related Terms
LTS:0PMJ vs ABT, SYK, MDT: 9-Day RSI Comparison
For the Medical Devices subindustry, Siemens Healthineers AG's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Siemens Healthineers AG 9-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Siemens Healthineers AG's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Siemens Healthineers AG's 9-Day RSI falls into.
Siemens Healthineers AG (LTS:0PMJ) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Siemens Healthineers AG (LTS:0PMJ) has a 9-Day RSI of 56.36 as of Jul. 19, 2026. According to the industry distribution chart, Siemens Healthineers AG ranks #638 out of 867 companies in the Medical Devices & Instruments industry, placing it in the top 73.6%.
Is Siemens Healthineers AG's 9-Day RSI too high?
Siemens Healthineers AG's current 9-Day RSI is 56.36. The Medical Devices & Instruments industry median 9-Day RSI is 45.51. Siemens Healthineers AG's value of 56.36 is 23.8% above this industry median. Based on the distribution chart, Siemens Healthineers AG ranks #638 out of 867 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Siemens Healthineers AG has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Siemens Healthineers AG's 9-Day RSI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Siemens Healthineers AG ranks #638 out of 867 companies for 9-Day RSI. This places Siemens Healthineers AG in the lower half of its industry. The industry median 9-Day RSI is 45.51. Siemens Healthineers AG's value of 56.36 is 23.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Devices & Instruments company?
The median 9-Day RSI among Medical Devices & Instruments companies is 45.51, based on 867 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Siemens Healthineers AG's current 9-Day RSI of 56.36 is 23.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median 9-Day RSI is 45.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Siemens Healthineers AG's current 9-Day RSI is 56.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Siemens Healthineers AG stock overvalued right now?
Based on GuruFocus' analysis, Siemens Healthineers AG (LTS:0PMJ) is currently considered Possible Value Trap. The stock's GF Value™ is €52.30, compared to a current price of €35.19 — trading 32.7% below its estimated fair value. The current 9-Day RSI is 56.36 and 23.8% above the Medical Devices & Instruments industry median of 45.51. Siemens Healthineers AG's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Siemens Healthineers AG (LTS:0PMJ), the current 9-Day RSI is 56.36 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Siemens Healthineers AG (LTS:0PMJ) Overvalued in 2026?
Based on GuruFocus' analysis, Siemens Healthineers AG stock appears to be undervalued.
The current stock price of €35.19 is trading 32.7% below its estimated GF Value™ of €52.30.
GuruFocus considers Siemens Healthineers AG to be Possible Value Trap.
Key valuation signals for LTS:0PMJ:
9-Day RSI: 56.36
GF Value™: €52.30 vs. price of €35.19 (32.7% below fair value)
Industry Position: 23.8% above the Medical Devices & Instruments median (#638 of 867)
No single metric tells the full story. See the LTS:0PMJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Siemens Healthineers is engaged in therapeutic imaging, radiotherapy, laboratory, and point-of-care diagnostics. The imaging segment (56% of sales in fiscal 2025) includes magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound. The Varian segment (18% of sales) offers radiotherapy and other oncology solutions. The diagnostics segment (19%) includes in vitro diagnostics and point-of-care diagnostics. The advanced therapies (now part of precision therapy) segment (9%) products are designed to support image-guided minimally invasive treatments in cardiology, interventional radiology, and surgery. The Americas represents 44% of total sales, Europe, Middle East, and Africa 32%, and Asia-Pacific, including China (11%), the remainder.
78GF Score
Get the complete analysis for LTS:0PMJ
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0PMJ has been successfully added to your 
